Following the milestones of printing a beating heart using patient's cells in 2019, the industry is eyeing the untapped potential offered by 3D organoids, organ-on-chips and for the first time, multi-organ systems - which will increase translatability, predictiveness of efficacy and toxicity before progressing to clinic.
The 5th Annual PREDiCT: 3D Oncology and Tissue Models Summit will return digitally this September, with a fresh speaker lineup,
bringing together preclinical scientists to discuss adoption and commercialization of 3D models as an integral part of drug
This 2-day digital summit will feature over 30+ senior preclinical scientists from oncology to cardiovascular to musculoskeletal and CNS backgrounds, to share their latest data and lessons learned from clinically translatable 3D models, to disease modeling of mechanisms, to attempting complex multi-cellular/organ systems to boost our understanding of functionality and physiological relevancy.
Embark on the 3D trailblazing community to boost your confidence of 3D models and accelerate bench to bedside drug development to provide a truly safe, and effective treatment for patients!
Why This is an Unmissable Event?
Whether you are an evaluator or early adopter of 3D models, working in oncology or general disease areas, the 5th annual meeting's case studies and expert speakers will help you:
* Accelerate the commercialization of 3D models and incorporate this as your integral drug development process
* Discover unpublished scientific data and lessons learned from both drug developers and academia - boosting your confidence in 3D models and informing your future R and D decisions
* Improve your models' translatability and predictiveness to fast track into the clinic with confidence
* Develop, validate and implement tissue-on-chip and novel multi-organ-on-chip systems through hands-on workshops
* Benchmark and network with committed 3D model pioneers - sparking long-term scientific collaborations
Pharma, Biotech and Academic (T and Cs Apply): USD 0.0,
Model Developers and Service Providers: USD 3499.0
Speakers: Terry Van Vleet, Abbvie, Aaron Fullerton, Genentech, Szczepan Baran, Novartis, Stefan Przyborski, Durham University, Piyush Bajaj, Sanofi, Hansjoerg Keller, Novartis, MinJae Song, National Institute of Health Sciences, Niresh Hariparsad, Vertex Pharmaceuticals, Guohao Dai, Northeastern University, Jason Ekert, GlaxoSmithKline, Passley Hargrove-Grimes, NCATS/NIH, Rhiannon David, AstraZeneca, Graham Marsh, Biogen, Ibrahim Ozbolat, Penn State, Jinping Gan, Bristol-Myers Squibb, Goran Landberg, University of Gothenburg, Linda Lieberman, Merck and Co, Denise de Almeida Nagata, Genentech, Misti Ushio, Tara Biosystems, Nicholas A. Geisse, NanoSurface Biomedical Inc., Joseph Charest, Draper, Suzanne Fitzpatrick, US Food and Drug Administration (FDA), Andreas Stahl, UC Berkeley, Norman Peterson, Biopharmaceutical Development and Life Sciences, Alice Soragni, UCLA, Olivier Bonneau, Novartis Institutes for BioMedical Research (NIBR), Evelyn Aranda, XYLYX Bio, G. Wesley Hatfield, Aracari Biosciences, James J. Hickman, University Central Florida, Joep Beumer, Hubrecht Institute, Ashutosh Agarwal, University of Miami, Trivia Frazier, Obatala Sciences
Time: 9:00 am to 6:00 pm